Papandreou, A;
McTague, A;
Trump, N;
Ambegaonkar, G;
Ngoh, A;
Meyer, E;
Scott, RH;
(2016)
GABRB3 mutations: a new and emerging cause of early infantile epileptic encephalopathy.
Developmental Medicine and Child Neurology
, 58
(4)
pp. 416-420.
10.1111/dmcn.12976.
|
Text
Papandreou_et_al-Developmental_Medicine_&_Child_Neurology.pdf Download (439kB) | Preview |
Abstract
The gamma-aminobutyric acid type A receptor β3 gene (GABRB3) encodes the β3-subunit of the gamma-aminobutyric acid type A (GABAA ) receptor, which mediates inhibitory signalling within the central nervous system. Recently, GABRB3 mutations have been identified in a few patients with infantile spasms and Lennox-Gastaut syndrome. We report the clinical and electrographic features of a novel case of GABRB3-related early-onset epileptic encephalopathy. Our patient presented with neonatal hypotonia and feeding difficulties, then developed pharmacoresistant epileptic encephalopathy, characterized by multiple seizure types from 3 months of age. Electroencephalography demonstrated ictal generalized and interictal multifocal epileptiform abnormalities. Using a SureSelectXT custom multiple gene panel covering 48 early infantile epileptic encephalopathy/developmental delay genes, a novel de novo GABRB3 heterozygous missense mutation, c.860C>T (p.Thr287Ile), was identified and confirmed on Sanger sequencing. GABRB3 is an emerging cause of early-onset epilepsy. Novel genetic technologies, such as whole-exome/genome sequencing and multiple gene panels, will undoubtedly identify further cases, allowing more detailed electroclinical delineation of the GABRB3-related genotypic and phenotypic spectra.
Archive Staff Only
 |
View Item |
